rolled out top-line phase III data from Triumph-1 showing that all doses of retatrutide met primary and key secondary endpoints for obesity, with participants losing on average between 19% and 28.3% of body weight and significantly improving their cardiovascular risk factors
EBioMedicine (2019) 46:47385
Sikiric P, Seiwerth S, Rucman R, et al
Patients should not seek retatrutide from unregulated online sources, as unlicensed products carry serious risks including contamination and unknown safety profiles
In clinical trials, doses are escalated gradually over several weeks to improve tolerability a process known as dose titration
Amber glass vials or nitrogen-sealed aluminum bags provide primary barriers against environmental degradation, while secondary packaging including desiccant packets absorbs residual moisture that could compromise peptide stability